CFTR and ENaC functions in cystic fibrosis

被引:0
|
作者
Palma, Alejandra G. [1 ]
Kotsias, Basilio A. [1 ]
Marino, Gabriela I. [1 ]
机构
[1] Univ Buenos Aires, IDIM CONICET, Inst Invest Med Alfredo Lanari, Lab Cana Ion, Buenos Aires, DF, Argentina
关键词
cystic fibrosis; CFTR; ENaC; ionic movements; cytoskeleton; TRANSMEMBRANE CONDUCTANCE REGULATOR; GAP-JUNCTION CHANNELS; MUTATIONS; GENE; EXPRESSION; DELTA-F508; TRANSPORT; AMILORIDE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cystic fibrosis is caused by dysfunction or lack of the cystic fibrosis transmembrane conductance regulator (CFTR), a chloride channel that has a key role in maintaining ion and water honnoeostasis in different tissues. CFTR is a cyclic AMP-activated Cl- channel found in the apical and basal plasma membrane of airway, intestinal, and exocrine epithelial cells. One of CFTR's primary roles in the lungs is to maintain homoeostasis of the airway surface liquid layer through its function as a chloride channel and its regulation of the epithelial sodium channel ENaC. More than 1900 CFTR mutations have been identified in the cftr gene. The disease is characterized by viscous secretions of the exocrine glands in multiple organs and elevated levels of sweat sodium chloride. In cystic fibrosis, salt and fluid absorption is prevented by the loss of CFTR and ENaC is not appropriately regulated, resulting in increased fluid and sodium resorption from the airways and formation of a contracted viscous surface liquid layer. In the sweat glands both Na+ and Cl- ions are retained in the lumen, causing significant loss of electrolytes during sweating. Thus, elevated sweat NaCl concentration is the basis of the classic pilocarpine-induced sweat test as a diagnostic feature of the disease. Here we discuss the ion movement of Cl- and Na+ ions in two tissues, sweat glands and in the air surface as well as the role of ENaC in the pathogenesis of cystic fibrosis.
引用
收藏
页码:133 / 139
页数:7
相关论文
共 50 条
  • [1] Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease
    Fajac, I.
    Viel, M.
    Gaitchi, N.
    Hubert, D.
    Bienvenu, T.
    EUROPEAN RESPIRATORY JOURNAL, 2009, 34 (03) : 772 - 773
  • [2] ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
    Mall, Marcus A.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (06)
  • [3] The effect of ambroxol on chloride transport, CFTR and ENaC in cystic fibrosis airway epithelial cells
    Varelogianni, Georgia
    Hussain, Rashida
    Strid, Hilja
    Oliynyk, Igor
    Roomans, Godfried M.
    Johannesson, Marie
    CELL BIOLOGY INTERNATIONAL, 2013, 37 (11) : 1149 - 1156
  • [4] Cystic fibrosis and CFTR
    R. Greger
    R. Schreiber
    M. Mall
    A. Wissner
    A. Hopf
    M. Briel
    M. Bleich
    R. Warth
    K. Kunzelmann
    Pflügers Archiv, 2001, 443 (Suppl 1): : S3 - S7
  • [5] Cystic fibrosis and CFTR
    Greger, R
    Schreiber, R
    Mall, M
    Wissner, A
    Hopf, A
    Briel, M
    Bleich, M
    Warth, R
    Kunzelmann, K
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2001, 443 : S3 - S7
  • [6] ENaC inhibitors for the treatment of cystic fibrosis
    Butler, Rebecca
    Hunt, Thomas
    Smith, Nichola J.
    PHARMACEUTICAL PATENT ANALYST, 2015, 4 (01) : 17 - 27
  • [7] ENaC Targeted Therapy for Cystic Fibrosis
    Dalbay, Melis Tugce
    Baines, Deborah
    Woodall, Max
    O'Callaghan, Christopher
    Hart, Stephen L.
    MOLECULAR THERAPY, 2020, 28 (04) : 460 - 460
  • [8] CFTR structure and cystic fibrosis
    Cant, Natasha
    Pollock, Naomi
    Ford, Robert C.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2014, 52 : 15 - 25
  • [9] CFTR gene and cystic fibrosis
    Gaskin, KJ
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (02) : 228 - 228
  • [10] CFTR MODULATORS FOR CYSTIC FIBROSIS
    Passi, Gouri Rao
    INDIAN PEDIATRICS, 2017, 54 (12) : 1060 - 1060